Experimental Bladder Cancer Drug Shows Promising Results in Clinical Trial
Breakthrough in Bladder Cancer Treatment: Sasanlimab Shows Promising Results in Phase 3 Trial In a notable advancement for bladder cancer treatment, the experimental drug sasanlimab, developed by Pfizer, has demonstrated promising results in a phase 3 clinical trial. The drug, an anti-PD-1 monoclonal antibody, was tested in combination with the BCG (Bacillus Calmette-Guérin) vaccine, a … Read more